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Abstract
Background: Venom immunotherapy (VIT) is the only effective treatment for prevention of
serious allergic reactions to bee and wasp stings in sensitized individuals. However, there are still
many questions and controversies regarding immunotherapy, like selection of the appropriate
allergen, safety and long term efficacy.
Methods: Literature review was performed to address the role of basophil activation test (BAT)
in diagnosis of venom allergy.
Results: In patients with positive skin tests or specific IgE to both honeybee and wasp venom, IgE
inhibition test can identify sensitizing allergen only in around 15% and basophil activation test
increases the identification rate to around one third of double positive patients. BAT is also
diagnostic in majority of patients with systemic reactions after insect stings and no detectable IgE.
High basophil sensitivity to allergen is associated with a risk of side effects during VIT. Persistence
of high basophil sensitivity also predicts a treatment failure of VIT.
Conclusion:  BAT is a useful tool for better selection of allergen for immunotherapy, for
identification of patients prone to side effects and patients who might be treatment failures.
However, long term studies are needed to evaluate the accuracy of the test.
Introduction
Up to 0.1% of the population suffers from severe anaphy-
laxis after Hymenoptera insect sting. The prevalence is
even higher in beekeepers, where can exceed 4% [1].
Venom immunotherapy (VIT) is the only effective treat-
ment for prevention of serious allergic reactions to bee
and wasp stings in sensitized individuals. However, there
are still many questions and controversies regarding
immunotherapy, like selection of the appropriate venom
in patients with double positive tests or of patients with
allergic reactions following European hornet stings,
patients with negative sIgE and skin tests, detecting the
patients at risk for side effects during immunotherapy and
detecting the patients at risk of relapse after stopping
immunotherapy [2].
Patients with positive allergy tests to both 
honeybee and wasp venom
Up to 50% of patients with sting reactions have positive
routine diagnostic tests (skin tests, specific IgE) to both
honeybee and wasp venom. True double sensitization and
cross-reactivity must be considered as a cause of the dou-
ble positivity and diagnosed in this group of patients [3].
Cross-reactivity is possible on the protein level most often
through venom hyaluronidases or through carbohydrates
epitopes (CCD) [4,5]. Distinguishing between double
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sensitization and cross-reactivity is crucial for the choice
of a proper allergen for specific immunotherapy in
patients who didn't recognize the culprit insect [6].
Namely, patients should be treated with the venom,
which induced sensitization. Immunotherapy with the
venom to which a patient is not primarily sensitised can
lead to an incomplete protection and treatment failure.
On the other hand, treatment with a cross-reactive venom
only or a mixture of venoms can lead to the formation of
sIgE against epitopes to which the patient was not sensi-
tised prior to immunotherapy [7,8].
If double sensitization is proven in a patient, who did not
recognize the culprit insect, immunotherapy should be
performed with both venoms; if cross - reactivity is the
case, immunotherapy should be performed only with the
venom that caused sensitization. Using specific IgE inhibi-
tion tests, Straumann was able to identify the insect that
caused sensitisation in 4 out of 24 double positive
patients [3]. We performed basophil activation tests (BAT)
in 25 bee and wasp double positive patients and were able
to characterize primary sensitization in one third of them
(nearly all were found to be wasp allergic) [9]. BAT is a
flow cytometry based test, which measures basophil acti-
vation markers like CD63 on surface of basophils after
cells are stimulated in-vitro with allergen. We found some
additional benefit of BAT over sIgE as basophils are not
activated by clinically unimportant sIgE antibodies
against CCD. BAT was shown to have higher specificity
compared to sIgE, retaining higher sensitivity compared
to skin tests. Moreover, the BAT test was feasible also in
patients with very low level of sIgE, where inhibition tests
were not possible.
Immunotherapy of patients with allergic 
reactions following European hornet stings
In Europe, wasp stings are responsible for most Vespidae
venom allergic reactions and only occasional reactions are
caused by European hornet (Vespa crabro) stings. How-
ever, those reactions are very likely to be severe: the rela-
tive risk for life-threatening reactions after a Vespa crabro
sting is about three times higher than it is for a honeybee
or yellow jacket sting [10]. Those patients usually have
positive skin tests and specific IgE to all Vespoidea ven-
oms (Vespula germanica, Vespa crabro and also paper wasp
[Polistes]).
In order to distinguish primary sensitisation from cross-
reactivity, we performed cross inhibition tests in 24 con-
secutive patients who experienced anaphylactic reaction
after European hornet stings: 17/24 patients were sensi-
tised with only wasp (Vespula germanica) venom, 2/24
with completely cross-reactive epitopes, 1 with only Euro-
pean hornet venom and 4 with separate epitopes of both
venoms [11]. We concluded that in Europe at least 70% of
patients that experienced a systemic allergic reaction after
European hornet stings were actually allergic to wasp
venom. The logical conclusion from this observation
would be that Vespula germanica venom remains the most
appropriate immunotherapeutic agent for the majority of
those patients.
Anaphylaxis in patients with negative allergy 
tests
Although sIgE are believed to be the cause of allergic reac-
tions after Hymenoptera insect stings, around 4% of
patients with repeated systemic reactions and no detecta-
ble IgE [12,13]. Current guidelines for VIT suggest that
immunotherapy should be performed only in patients
with an IgE-mediated systemic reaction [6], but opinions
about the diagnosis and treatment of patients with sys-
temic reaction without IgE vary widely [2]. Some have
proposed submitting every patient with a history of
Hymenoptera sting allergy and negative allergy tests to a
provocation test [14]. Negative skin test and no specific
IgE may indicate a non-allergic reaction or a limited diag-
nostic sensitivity of the test. An alternative mechanism
that could activate mast cells in the absence of sIgE is com-
plement activation and the generation of anaphylatoxin
C5a [15,16].
However, we found that 75% of 47 sIgE negative patients
had a positive reaction in the flow cytometry based
basophil activation test [17]. Even better results were
shown by Ebo, who was able to identify sensitisation with
a BAT test in 7 out of 7 sIgE negative patients [18]. The
limitation of those studies is that due to ethical reasons
the clinical history and not a sting challenge was used as a
gold standard. However it has been shown that BAT test
very rarely gives false positive results [19].
Safety of VIT
In different immunotherapy protocols a cumulative dose
of 100 μg of venom (corresponding to 2 honeybee or 10
wasp stings) is reached in few hours or days with no aller-
gic reactions in the majority of patients, however at least
15% of patients exhibit systemic allergic reactions [20,21].
We investigated whether adult patients prone to systemic
reaction during immunotherapy could be identified on
the basis of basophil sensitivity to allergen [22]. We
expressed the sensitivity as a ratio between basophil
response to two concentrations of allergen. The first con-
centration (0.1 μg/ml) was shown in previous experi-
ments as submaximal, eliciting only a partial activation of
basophils in majority of tested subjects, and the second
concentration (1 μg/ml) was maximal and elicited a com-
plete activation of basophils in all responding subjects (it
has to be stressed, that basophils of about 5% of patients
do not respond at all to stimulation, and those patients
are not suitable for BAT test). For each patient we calcu-Allergy, Asthma & Clinical Immunology 2009, 5:11 http://www.aacijournal.com/content/5/1/11
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lated the ratio between basophil CD63 expression after
stimulation with allergen in a concentration 0.1 and 1 μg/
ml (0.1/1 ratio). Twelve out of 34 patients had reaction to
VIT. In those 12 patients median 0.1/1 ratio was 0,99
(range: 0.17-1.95) Side-effects occurred in all patients
with 0.1/1 ratios over 0.92. In contrast, in 22 patients with
no side effects, the median 0.1/1 ratio was 0.25 (range:
0.02-0.92). These concentration-dependent activation
ratios were significantly different between the groups with
and without side reactions (P < 0.0001). Our results sug-
gest that high basophil sensitivity to allergen is signifi-
cantly associated with a risk of side effects to VIT. Similar
results were obtained also in the children [23]. In the
same study we showed that an elevated basal tryptase level
was not a predicting factor for side effects of VIT [22].
Effectiveness of VIT
Rush immunotherapy is very effective. Nearly complete
tolerance after only a few days of VIT has been confirmed
[24]. Immunotherapy is associated with an improved
quality of life [25,26]
Long-term effectiveness after stopping the treatment is less
reliable: in a Swiss study, 16% of bee allergic patients and
7.5% of wasp allergic patients treated for 3 to 7 years
developed systemic reactions after stopping VIT; most
reactions were mild, but there was a tendency for an
increase in the severity of reactions after repeated re-sting-
ing [27]. Moreover, a fatal reaction 9 years after the dis-
continuation of immunotherapy was recently described
[28]. Some risk factors for relapse after immunotherapy
are recognized [20]:
• Bee venom allergy
￿ Severe pre-treatment reaction
￿ Reaction to VIT injection
￿ Reaction during VIT
￿ Duration of VIT < 5 years
￿ Repeated re-stings after stopping VIT
Patients with reactions during immunotherapy are
encouraged to receive immunotherapy indefinitely.
In our survey 229 patients treated with VIT between 1984
and 2004 were sent a questionnaire inquiring whether
they had been stung by an insect to which the VIT had
been directed [29]. 79% received VIT for more than 3
years and 55% were stung after discontinuing VIT. At the
time of the first sting after stopping VIT, 8 (8%) had a sys-
temic reaction. There were 40 patients who were stung
more than once after ending VIT, among whom 7 (17.5%)
experienced reactions of greater severity with the subse-
quent stings. All patients reported that their reactions after
ending VIT were milder than before treatment. The likeli-
hood of systemic reactions to stings was almost identical
in patients treated for either more than or less than 3 years
with VIT. Furthermore, patients who reacted after discon-
tinuation of immunotherapy had higher basophil sensi-
tivity (the sensitivity was comparable to a group of
patients without immunotherapy) compared to a group
of protected patients [30].
Conclusion
Venom immunotherapy is very, but not completely, effec-
tive. However, managing patients with venom hypersensi-
tivity has become less straightforward than it seemed to be
some time ago. Diagnostic tests may be misleading and
could pose problems regarding the selection of the appro-
priate venom for immunotherapy. The mechanisms of
tolerance during first days of VIT are still to be docu-
mented. The long-term effectiveness of VIT is questiona-
ble. The basophil activation test appears to be a useful tool
for better selection of allergen for immunotherapy, for
identification of patients prone to side effects and patients
who might be treatment failures. However, more long
term studies are needed to evaluate the accuracy of the
test.
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